Viewing Study NCT02227251


Ignite Creation Date: 2025-12-24 @ 11:52 PM
Ignite Modification Date: 2026-01-06 @ 6:02 AM
Study NCT ID: NCT02227251
Status: RECRUITING
Last Update Posted: 2025-10-01
First Post: 2014-08-12
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Sponsor: Karyopharm Therapeutics Inc
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module